Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

Shares of Amgen Inc. AMGN advanced 1.99% to $319.10 Thursday, on what proved to be an all-around great trading session for ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...

Cantor Fitzgerald initiated coverage of Amgen with an Overweight rating and $405 price target. The firm views Amgen’s obesity ...

Cantor initiated Amgen (AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech company’s ...

Fintel reports that on September 27, 2024, Cantor Fitzgerald initiated coverage of Amgen (NasdaqGS:AMGN) with a Overweight ...

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $326.38, a high estimate of $381 ...

On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...

As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...